Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties
Background Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must take place without impairing the structure and function of the biologics. This study investigated the effect of withdrawing and storing the therapeutic antibody faricimab (Vabysmo, Roche, Basel, Switzerland) in the Zero Residual silicone oil-free, 0.2-mL syringe (SJJ Solutions, The Hague, the Netherlands). Methods To assess the effect of syringe withdrawal on faricimab, we compared samples from syringes prepared at day 0 with samples taken directly from faricimab vials. To assess the effect of syringe storage on faricimab, we kept prefilled syringes in the dark at 4 oC for 7, 14, or 37 days and compared samples from these syringes with day 0. We measured protein concentration (with spectrophotometry), stability and integrity (with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), size-exclusion chromatography (SEC), and melting temperature (Tm)), as well as binding of faricimab to its cognate antigens: vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2) (with enzyme-linked immunosorbent assay (ELISA)). Results Faricimab migrated in line with its expected molecular mass under both reducing and non-reducing conditions for all time points when analyzed with SDS-PAGE, without any sign of degradation products or aggregation. The SEC elution profiles were identical for all time points. There were slight variations in Tm for different time points compared to day 0 but without consistent relationship with storage time. ELISA did not detect differences in VEGF-A or Ang-2 binding between time points, and faricimab did not bind the neonatal Fc receptor. Conclusions Withdrawal and storage of faricimab in syringes for up to day 37 did not impair the structure and bi-specific binding properties of the therapeutic antibody..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
International Journal of Retina and Vitreous - 9(2023), 1 vom: 07. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jørstad, Øystein Kalsnes [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Bi-specific binding |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s40942-023-00507-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053659775 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053659775 | ||
| 003 | DE-627 | ||
| 005 | 20231108064645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231108s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40942-023-00507-3 |2 doi | |
| 035 | |a (DE-627)SPR053659775 | ||
| 035 | |a (SPR)s40942-023-00507-3-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jørstad, Øystein Kalsnes |e verfasserin |0 (orcid)0000-0003-1259-0653 |4 aut | |
| 245 | 1 | 0 | |a Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Intravitreal injection (IVI) of antibody biologics is a key treatment approach in ophthalmology. Pharmaceutical compounding and storage of prefilled syringes for IVI must take place without impairing the structure and function of the biologics. This study investigated the effect of withdrawing and storing the therapeutic antibody faricimab (Vabysmo, Roche, Basel, Switzerland) in the Zero Residual silicone oil-free, 0.2-mL syringe (SJJ Solutions, The Hague, the Netherlands). Methods To assess the effect of syringe withdrawal on faricimab, we compared samples from syringes prepared at day 0 with samples taken directly from faricimab vials. To assess the effect of syringe storage on faricimab, we kept prefilled syringes in the dark at 4 oC for 7, 14, or 37 days and compared samples from these syringes with day 0. We measured protein concentration (with spectrophotometry), stability and integrity (with sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), size-exclusion chromatography (SEC), and melting temperature (Tm)), as well as binding of faricimab to its cognate antigens: vascular endothelial growth factor A (VEGF-A) and angiopoietin-2 (Ang-2) (with enzyme-linked immunosorbent assay (ELISA)). Results Faricimab migrated in line with its expected molecular mass under both reducing and non-reducing conditions for all time points when analyzed with SDS-PAGE, without any sign of degradation products or aggregation. The SEC elution profiles were identical for all time points. There were slight variations in Tm for different time points compared to day 0 but without consistent relationship with storage time. ELISA did not detect differences in VEGF-A or Ang-2 binding between time points, and faricimab did not bind the neonatal Fc receptor. Conclusions Withdrawal and storage of faricimab in syringes for up to day 37 did not impair the structure and bi-specific binding properties of the therapeutic antibody. | ||
| 650 | 4 | |a Intravitreal injection |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Faricimab |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Compounding pharmacy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Prefilled syringes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Bi-specific binding |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Foss, Stian |4 aut | |
| 700 | 1 | |a Gjølberg, Torleif Tollefsrud |4 aut | |
| 700 | 1 | |a Mester, Simone |4 aut | |
| 700 | 1 | |a Nyquist-Andersen, Mari |4 aut | |
| 700 | 1 | |a Sivertsen, Magne Sand |4 aut | |
| 700 | 1 | |a Fossum, Dag |4 aut | |
| 700 | 1 | |a Gleditsch, Espen |4 aut | |
| 700 | 1 | |a Moe, Morten Carstens |4 aut | |
| 700 | 1 | |a Andersen, Jan Terje |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International Journal of Retina and Vitreous |d London : BioMed Central, 2015 |g 9(2023), 1 vom: 07. Nov. |w (DE-627)SPR037994506 |w (DE-600)2836254-8 |x 2056-9920 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:1 |g day:07 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40942-023-00507-3 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 1 |b 07 |c 11 | ||